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Abstract
Purpose Psychological problems are frequently mentioned
in women treated for breast cancer in whom depression is
mentioned as the most common disorder. The aim was to
study the prescription of psychotropic medication in
women with endocrine treatment for breast cancer in
women in our prospective and consecutive pharmacy
database.
Methods Women (n=2,172) with at least one prescription
of tamoxifen, fulvestrant, anastrazole, letrozole or exemes-
tane were considered as breast cancer patients treated with
endocrine therapy. This group was compared with an age-
and family physician-matched group of women without
cancer (n=8,129), and the incidence risk ratio (IRR) and
the 95% confidence intervals (95% CI) were calculated. In
addition, the prevalence of these psychotropic medication
prescriptions and the 95% CI were calculated.
ResultsThere was an increased prescription of psychotropic
medication in the female breast cancer patients on endocrine
therapy: anxiolytics (IRR 2.07, 95% CI 1.87–2.29), hyp-
notics and sedatives (IRR 2.59, 95% CI 2.34–2.87) and anti-
depressants (IRR 1.46, 95% CI 1.28–1.65). The prevalences
of anxiolytics, hypnotics and sedatives were also increased in
this group, indicating an increased use over time of these
drugs. The prevalence of anti-depressant prescription was not
increased, indicating short-term use only.
Conclusions This study indicated increased psychological
distress due to breast cancer diagnosis and/or treatment in
women on endocrine therapy. Anti-depressants were only
prescribed for a short time. These data can contribute to an
improved awareness of the impact of breast cancer
(treatment) and therefore potentially to the optimizing of
support for these patients.
Keywords Breast cancer survivor.Endocrine treatment.
Psychotropic medication.Quality of life.Depression
Introduction
Breast cancer is the most prevalent type of cancer among
women [1]. Endocrine therapy is an essential part of the
adjuvant treatment for oestrogen receptor-positive and/or
progesterone receptor-positive breast cancer [2]. This
treatment exerts its effect by reducing the availability of
oestrogen to micro-metastatic tumour cells. Meta-analyses
have shown the efficacy of this treatment in improving
disease-free and overall survival in women with early-stage
as well as advanced breast cancer [3–7]. Current treatment
standards involve (≥) 5 years of endocrine therapy,
including tamoxifen for premenopausal women and aroma-
tase inhibitors for postmenopausal women.
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younger women) treated for an extensive period of time is
increasing, there is increased concern about long-term
treatment-related symptoms and psychological well-being
[8]. A better understanding of the psychosocial consequen-
ces of breast cancer on the quality of life after breast cancer
can assist in recommendations for future treatment [9]. In a
review including 125 references on psychosocial function-
ing of survivors of breast cancer, it is concluded that the
majority of breast cancer survivors adjusted well 2 years
since their first diagnosis. However, there is a subgroup of
survivors reporting after-treatment psychological distress.
The estimates for this group range from 5% to 50% [8].
We hypothesized that psychological distress accompa-
nied with breast cancer diagnosis and/or the side effects of
adjuvant therapy leads to an increased use of psychotropic
medication in female breast cancer patients treated with
endocrine therapy. Therefore, we assessed the use of
psychotropic medication in female patients treated with
endocrine therapy over time and compared the use of
psychotropic medication with an age- and family physician-
matched cohort of women without cancer.
Patients and methods
Drug prescription data
The IADB is situated in the North of the Netherlands,
covering an area of 3.4 million inhabitants. The IADB.nl is
a pharmacy drug prescription database in the North of the
Netherlands covering a population of 500,000. All pre-
scriptions for persons livi n gi nt h eI A D Ba r e aa r e
prospectively and consecutively entered into the pharmacy
database. These prescriptions are, regardless of prescriber,
insurance or reimbursement status, except over-the-counter
(OTC) drugs and drugs dispensed during a hospital stay. So,
all prescribed drugs (except in hospital use and OTC drugs)
delivered to this population are available in the database.
We have compared the drug use in our database with
national prescription databases and found for all main drug
groups comparable prevalences of drug use among sex and
different age groups. Based on that, the IADB.nl can be
considered as a database that is representative for the
Netherlands regarding drug exposure. We have a method-
ological article in preparation on this topic.
Each prescription record comprises information about
the drug, side effects, date of dispensing, amount dispensed,
dose regimen and the prescribing physician. The indication
for the prescription is not known. All drugs are coded
according to the Anatomical Therapeutic Chemical (ATC)
classification [11, 12]. For each patient, there are sex, date
of birth, family physician and a unique, anonymous
identifier. Due to a high patient pharmacy commitment in
the Netherlands and sophisticated pharmacy software, the
prescription records for each patient are virtually complete
[13].
The role of the general practitioner
In the Netherlands, general practitioners hold a key position
in health care. They are the first health care professionals to
see people when they are ill, and they act as gatekeepers to
secondary care. Most cases that present to a general practice
are taken care of by the general practitioner alone.
Sometime after primary treatment, the care for the patient
is shifted back from hospital to general practice. When the
care for the patient is shifted back to general practice, the
general practitioner is responsible for the prescription of
drugs. The most common indication for prescribing drugs
in general practice is cardiovascular diseases, followed by
diabetes mellitus and depression, respectively [14].
Females treated with endocrine therapy
In the Netherlands, endocrine and psychotropic medications
are prescription drugs and cannot be obtained OTC. In the
Netherlands, endocrine therapy is not indicated for the
prevention of breast cancer, also not in high-risk women.
All women who were over 20 years of age during the
study period 1994–2006 and had at least one prescription of
anti-oestrogens (tamoxifen, fulvestrant) or aromatase inhib-
itors (anastrazole, letrozole, exemestane) were selected.
Women with at least one prescription of anti-oestrogens or
aromatase inhibitors were included in the analysis when
there was information in the IADB database for a minimum
of 180 days before the start date of adjuvant hormonal
treatment. The analysis was based on these anti-oestrogens
and aromatase inhibitors because these products are the
preferred endocrine treatments for breast cancer in the
Netherlands.
Women in the reference population
To compare the use of psychotropic medication among
women using anti-oestrogens with the use of psychotropic
medication among women not using anti-oestrogens, there
were two options. Firstly, we could use the data of all
women not using anti-oestrogens and correct for bias due to
age and time in follow-up in the analysis. The second
option was to draw a stratified sample of women not using
anti-oestrogens from the cohort and correct in this way for
bias due to age and time in follow-up. The reference
population included women without any prescription of
anti-oestrogens or aromatase inhibitors. In addition, women
with any prescription of anti-neoplastic and immuno-
1534 Support Care Cancer (2012) 20:1533–1540modulating agents (ATC classification group L) were
excluded. From this group, three to four women were
matched for age at the start date of the anti-oestrogens or
aromatase inhibitors prescription and family physician of
the women in the index group. This start date was
considered as the “theoretical” start date for women in the
reference population. Women in the reference population
could only be matched if there was information available in
the IADB for at least 180 days before the theoretical start
date. On average, there was a match of 3.7 reference
women per woman with hormone receptor-positive breast
cancer.
Psychotropic medication
Psychotropic medication was classified with the use of the
following ATC codes: N05B (anxiolytics), N05C (hypnotics
and sedatives) and N06A (anti-depressants).
Analyses
For females treated with endocrine therapy, the date of the
first prescription of anti-oestrogens or aromatase inhibitors
was considered as the starting date in the analysis. The
women from the reference population received the starting
date from the women with hormone receptor-positive breast
cancer to whom they were matched.
To assess whether the start of psychotropic medica-
tion was increased, the cohort of female breast cancer
survivors (index group, n=2,172) was compared with an
age- and family physician-matched group of women
without cancer (the reference population, n=8,129), and
the incidence risk ratio (IRR) and the 95% confidence
intervals (95% CI) were calculated. The IRR was
calculated as the incidence rate (IR) of the index group
divided by the IR of the reference group [10]. For
calculation of the IR, given the distribution of the data,
1 year before the starting date of adjuvant therapy was
chosen as the starting point for follow-up. The number of
patient days in the database was measured from this
starting point for follow-up up until either the prescription
date of psychotropic medication or the last known date of
that person in the database. The incidence of drug
prescribing was calculated as the number of incidence
cases divided by the total number of patient days at risk.
An incidence case was defined as a woman who did not
receive a prescription for this medication for the last
180 days.
To assess the prescriptions of psychotropic medication
over time, the half-year prevalence of these psychotropic
medication prescriptions and the 95% CIs were calculated
in the index as well as the reference group. The half-year
prevalence was defined as the proportion of women having
a psychotropic medication prescription during a half year
and was calculated as the number of women who use
psychotropic medication per 182 days (half year), divided
by the total number of women present in that period. All
statistical analyses were performed by Excel and SPSS
16.0. A p value of less than 0.05 was considered to be
statistically significant.
Results
The women in the study
In the IADB database, there were 2,172 female breast cancer
patients treated with endocrine therapy. The reference group
consisted of 8,129 women. The median age of the breast
cancer patients treated with endocrine therapy was 64 (20–
93), with a median follow-up time of 2.6 years. The median
age of women in the reference group was 62 (20–93), with a
medianfollow-up timeof3.8 years (seeTable1). The number
of women per year that started with tamoxifen, fulvestrant,
anastrazole, letrozole and exemestane is shown in Table 2.
Starting psychotropic medication
There are significantly more starting prescriptions of
psychotropic medication for female breast cancer patients
treated with endocrine therapy when compared to women in
the reference group (see Table 3). This increase is observed
for all three groups of psychotropic medication, anxiolytics
(IRR 2.07, 95% CI 1.87–2.29), hypnotics and sedatives
(IRR 2.59, 95% CI 2.34–2.87) and anti-depressants (IRR
1.46, 95% CI 1.28–1.65). Table 4 presents the specific
drugs in the three psychotropic groups that were mostly
prescribed. Of the 552 breast cancer patients who started
anxiolytics, 313 received oxazepam. Of the 580 who started
with hypnotics and sedatives, 383 received temazepam.
Among the 331 who started an anti-depressant, 144
received amitriptyline, and 66 (20%) received the combi-
nation paroxetine and tamoxifen (Table 4).
Psychotropic medication use
The prevalence of psychotropic medication use (anxio-
lytics, hypnotics and sedatives and anti-depressants) is
p r e s e n t e di nF i g .1. The prevalence of psychotropic
medication use (prevalence 0.45, 95% CI 0.43–0.47) is
significantly increased among breast cancer patients using
endocrine therapy when compared to the reference group
(prevalence 0.32, 95% CI 0.31–0.32). In the period a half
year after the start, there is still an increase of psychotropic
medication use, although from this period, a decrease is
observed.
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female breast cancer patients treated with endocrine therapy
is stratified for anxiolytics, hypnotics and sedatives and
anti-depressants. Before the start of hormonal therapy,
anxiolytics are most frequently prescribed, followed by
hypnotics and sedatives, and anti-depressants. After the
start of hormonal therapy, hypnotics and sedatives are
prescribed most frequently. In the period 6 months before
the start of hormonal therapy, the prevalences of anxiolytics
and hypnotics and sedatives are significantly increased as
compared with the use of these drugs longer before. For
anxiolytics, the prevalence is 0.26 (95% CI 0.24–0.27), and
for hypnotics and sedatives, the prevalence is 0.24 (95% CI
0.23–0.26) (Fig. 2). The prevalence of anti-depressant use
is not increased.
Discussion
This large cohort study examined the use of psychotropic
medication in women with breast cancer treated with
endocrine therapy (n=2,172) as compared to a group of
matched women without cancer (n=8,129). An increased
prescribing of psychotropic medication in these women
treated with endocrine therapy was shown, as was hypoth-
esized. There was an increased start for anxiolytics (IRR
Year Tamoxifen Fulvestrant Anastrazole Letrozole Exemestane
1994 8 0 0 0 0
1995 34 0 0 0 0
1996 54 0 0 0 0
1997 87 0 12 0 0
1998 158 0 40 1 0
1999 218 0 37 5 0
2000 218 0 36 23 6
2001 194 0 37 15 7
2002 197 0 57 22 27
2003 165 0 96 32 32
2004 159 0 88 54 45
2005 148 13 148 67 75
2006 149 21 123 83 53
Table 2 Number of starters per
year
A starter is defined as a woman
who did not receive a prescrip-
tion for this drug for at least
180 days. The database is rela-
tive stable since 1999
Index group
a Reference group
b
Number 2,172 8,129
Mean number of reference
women per index woman
1 3.7
Mean age at start date (SD) 64 years (15 years) 63 years (15 years)
Median (range) 64 years (20–93) 62 years (20–93)
Number of women
per age group
Age group n % n %
20–30 16 0.7 65 0.8
30–40 94 4.3 387 4.8
40–50 301 13.9 1,272 15.6
50–60 487 22.4 1,969 24.2
60–70 411 18.9 1,500 18.5
70–80 444 20.4 1,652 20.3
80–90 388 17.9 1,232 15.2
90– 31 1.4 52 0.6
Total 2,172 100 8,129 100
Total time in follow-up
c 7,287years 34,330 years
Mean (SD) 3.36 years (2.63 years) 4.22 years (2.85 years)
Median 2.64 years (0.02–12.74) 3.78 years (0.00–13.66)
Table 1 Characteristics of
women with hormone receptor-
positive breast cancer in the
index group and women in the
reference group
aIndex group—women with at
least one prescription of tamox-
ifen, fulvestrant, anastrazole,
letrozole or exemestane were
considered as breast cancer
patients treated with endocrine
therapy
bReference group—an age- and
family physician-matched group
of women any prescription of
tamoxifen, fulvestrant, anastra-
zole, letrozole or exemestane
cTime of follow-up—time in
observation
1536 Support Care Cancer (2012) 20:1533–15402.07, 95% CI 1.87–2.29), hypnotics and sedatives (IRR
2.59, 95% CI 2.34–2.87) and anti-depressants (IRR 1.46,
95% CI 1.28–1.65). Anxiolytics, hypnotics and sedatives
were used for a longer time, whereas such a continuous
increased use was not observed for anti-depressants.
Among the women with anti-depressants, 20% received
the drug combination of paroxetine and tamoxifen.
The increased percentage of women with breast cancer
starting to use anxiolytics, hypnotics, sedatives and anti-
depressants indicates that in these women, there is an
increased risk for psychological disorders. This is also
mentioned in literature. Psychological problems are fre-
quently mentioned in women treated for breast cancer,
though there is a wide range in the estimated incidence [8,
9, 15]. To give an example, in a study including 1,083
women with a history of breast cancer (median 4 years after
diagnosis) recruited through a population-based cancer
registry (66% response rate), 38% of patients reported
moderate to high anxiety, 22% moderate to high depression
and 12% posttraumatic disorder [16]. In addition, two
reviews on women with a history of breast cancer
concluded that there is a substantial effect of adjuvant
endocrine therapy on the health-related quality of life [9,
17]. Potential explanations for this impact on health-related
quality of life are side effects of treatment due to premature
menopause and mood disturbances [9]. High depression
and anxiety levels in patients after breast cancer influence
the coping with cancer and quality of life adversely [18].
We observed a statistically significant increase in the
prescription of anti-depressants (IRR 1.46, 95% CI 1.28–
1.65). The prevalence of depression among early breast
cancer women is estimated to be twice as many as that seen
in the general population [19]. In addition, in our study,
anxiolytics, hypnotics and sedatives were used for a longer
time, whereas such a continuous increased use was not
observed for anti-depressants. In literature, the increased
prevalence of depression in women with a history of breast
cancer is seen especially during the first year after diagnosis
[19]. It can be stated that depression is undertreated among
the breast cancer population [20]. On the other hand,
problems of depression are not always treated with anti-
depressants, but also with anxiolytics, hypnotics and
sedatives, and not all patients are willing to use medication
for their depressed feelings. One of the most prescribed
anti-depressants in this study was amitriptyline. In a low
dose, amitriptyline can be prescribed for neuropathy as well
as for sleep disturbances. As the prescribed dose distribution
of amitriptyline was equal for women with breast cancer
treated with endocrine therapy and for women without
cancer (data not presented), we expected no effect on the
presented incidence risk ratios. The relatively high preva-
lence of hypnotics (such as temazepam) and anti-depressants
after start of endocrine treatment may also be related to the
increased incidence of sleeping disorders due to hot flashes
as one of the menopausal symptoms after starting endocrine
treatment [21]. Improved sleeping quality on a combination
Table 4 Number of psychotropic drug users per group and specific drugs
Anxiolytics (N05B) n=552 Hypnotics and sedatives (N05C) n=580 Anti-depressants (N06A) n=331
Oxazepam 313 Temazepam 383 Amitriptyline 144
Diazepam 159 Lormetazepam 48 Paroxetine 66
Lorazepam 44 Nitrazepam 40 Venlafaxine 38
Alprazolam 11 Midazolam 37 Citalopram 25
Others 25 Zopiclon 34 Mirtazapine 19
Zolpidem 19 Others 39
Others 19
Table 3 Population at risk (n), incident cases (cases), incident rate (per 100,000 patient days) and IRR with 95% CI for psychotropic medication
Treatment class IRR (95% CI) Index (BC patients) (total n=2,172) Reference (no BC) (total n=8,129)
n Cases Days at risk IR n Cases Days at risk IR
Psychotropic medication
Anxiolytics 1,512 552 1,848,232 29.9 4,946 1,160 8,047,444 14.4 2.07 (1.87–2.29)
Hypnotics and sedatives 1,651 580 2,102,023 27,6 5,618 1,028 9,644,153 10.7 2.59 (2.34–2.87)
Anti-depressants 1,869 331 2,703,233 12,2 6,214 922 10,957,762 8.4 1.46 (1.28–1.65)
BC breast cancer
Support Care Cancer (2012) 20:1533–1540 1537of venlafaxine and anti-hypnotics was recently found to
contribute to improved quality of life in a similar group of
breast cancer patients [22].
There are many reported side effects associated with use
of psychotropic drugs. Side effects include but are not
limited to: dry mouth, blurred vision, constipation, urinary
retention, sedation, sleep disruption, weight gain or loss,
headache, nausea, agitation, inability to achieve an orgasm,
decreased libido and anxiety [clinicaldepression.com]. Long-
term use of anxiolytics has been a cause for concern because
of the possibility of dependency and other adverse conse-
quences. Long-term effects of anxiolytics are the following:
dependence, rebound anxiety, memory impairment and an
increased risk of falling in elderly persons taking benzodia-
zepines [23]. Among the women with anti-depressants, 20%
received the drug combination of paroxetine and tamoxifen.
The use of paroxetine in this study is remarkable. A recent
study showed that the use of paroxetine during tamoxifen
treatment is associated with an increased risk of death from
breast cancer [24]. Tamoxifen is a prodrug that is metab-
olised to active metabolite endoxifen by the hepatic
cytochrome P450 enzyme system. Paroxetine is a potent
irreversible CYP 2D6 inhibitor that can prevent the
metabolic activation of tamoxifen into the active metabolite
endoxifen. Based on the study of Kelly et al., it is
recommended to avoid this combination, and in case an
anti-depressant is necessary, an anti-depressant with little or
no inhibition of CYP 2D6 should be given. This is supported
in the recently published guidelines on the use of co-
medication with tamoxifen [25]. However, because only
short-term use of anti-depressants was found in this study,
this may narrow the scope of this issue.
A strong point of the analysis presented here is that the
used IADB database includes virtually complete prescrip-
tion records for the patients covered by this database,
except OTC drugs and drugs dispensed during a hospital
stay [13]. As neither psychotropic medication nor endocrine
therapies are OTC drugs in the Netherlands, this will not
influence the outcomes. The estimated population size
covered by the IADB.nl increased from 264.664 persons
Fig. 1 Prevalence of psychotro-
pic medication use in index and
reference groups. Medication
groups included: anxiolytics,
hypnotics and sedatives and
anti-depressants
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1538 Support Care Cancer (2012) 20:1533–1540in 1996 to approximately 500,000 persons in 1999 and has
remainedstablesince.Thewomenfromtheindexgroupcould
be considered as representative of the Dutch population. In
addition, the IADB.nl can be considered as a database that is
representative for the Netherlands regarding drug prescrip-
tions (manuscript in preparation). Regarding other prescrip-
tions, there were no differences between women from the
index group and women from the reference group.
A weak point is that there are no diagnoses of diseases in
this database. As we have very strict guidelines for the
prescription of endocrine treatment in the Netherlands [http://
www.oncoline.nl/], we were able to use a prescription of
endocrine treatment as a proxy for a diagnosis of breast
cancer. As a consequence, the following women were not
included in our analysis: women with hormone-negative
tumours, women with primary metastases and women with
very small tumours. As our included sample is large, we do
not expect that missing these groups might have a strong
impact on the presented incidence risk ratios. In addition, we
cannot analyse whether the increased use of psychotropic
medication among breast cancer patients treated with
endocrine treatment is related to the diagnosis of breast
cancer or the related treatment. There is no formal evaluation
of patients for mood disorder, anxiety or panic. We cannot be
certain that the increased use of psychotropic medication is
related to depression or anxiety. Benzodiazepines can also be
prescribed for sleep and anti-depressants for pain.
In conclusion, in this large cohort study on breast cancer
patients treated withendocrinetherapy, wefound anincreased
use of psychotropic medication, compared to the reference
group. This may be related to the reported increased
psychologicaldistressinthese patients. Anti-depressantswere
only prescribed for a short time. We do not know whether this
isrelatedtotheconditionofthepatientwithbreastcancerorto
the diagnostics of the prescriber. These data can contribute to
an improved awareness of the impact of breast cancer
(treatment) on quality of life and therefore potentially to the
optimizing of support for these patients.
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